Legal status · Canada
Is NNZ-2591 legal in Canada?
No. NNZ-2591 is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
NNZ-2591 in Canada at a glance
| Classification | Investigational, not approved |
|---|---|
| Health Canada approval status | Not approved by Health Canada; investigational |
| Evidence level | Preliminary (research strength: Moderate) |
| Reviewed | Sep 2026 |
Classification and note come from the NNZ-2591 profile, checked against Health Canada, Health Products and Food Branch (Health Canada) listings at the reviewed date.
What this means
- 01
NNZ-2591 is being studied in registered clinical trials but has not received Health Canada marketing approval in Canada.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What NNZ-2591 is
An oral IGF-1 metabolite mimic from the makers of trofinetide (Daybue), in the first-ever Phase 3 for Phelan-McDermid syndrome since February 2026.
NNZ-2591 is a synthetic analog of cyclic glycine-proline, a natural IGF-1 metabolite, and a sister molecule to trofinetide, which Neuren took to approval for Rett syndrome. It carries Fast Track, Orphan and Rare Pediatric designations.
Mechanism: Normalizes IGF-1 and synaptic signaling in the brain, improving neuronal connectivity in neurodevelopmental disorders.
Regulatory history: Investigational; Phase 3 (Fast Track, Orphan)
How Health Canada treats this kind of product
Authorises drugs for sale through a Notice of Compliance and Drug Identification Number. A compound that is not authorised for sale cannot lawfully be sold for human use, and personal importation of prescription drugs is limited.
The classification above is the The Longevity Archive reading of Health Canada, Health Products and Food Branch listings for NNZ-2591 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
NNZ-2591 in other countries
Frequently asked questions
Is NNZ-2591 legal in Canada?
No. NNZ-2591 is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
Can I buy NNZ-2591 in Canada?
No approved product exists to buy. In Canada NNZ-2591 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is NNZ-2591 Health Canada approved?
No. In Canada NNZ-2591 is classified as "Investigational, not approved", which is not a Health Canada marketing approval. For comparison, the US FDA status is: Investigational; Phase 3 (Fast Track, Orphan). Evidence level: Preliminary.
Related compounds in Canada
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for NNZ-2591 live on its compound profile.
NNZ-2591 profileThis page is general information about the regulatory status of NNZ-2591 in Canada, current as of Sep 2026. It is not legal advice, and classifications change; check Health Canada, Health Products and Food Branch directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.